Clinical Trials Logo

Clinical Trial Summary

This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and incidence of psychiatric co-morbidities in people with alopecia areata, (3) the prevalence and incidence of autoimmune and atopic conditions in people with alopecia areata, and (4) the incidence of common infections in people with alopecia areata.


Clinical Trial Description

The overall purpose of the first study (Study 1) is to describe the epidemiology of Alopecia areata (AA) and to assess the current level of primary care service utilisation and management patterns associated with patients diagnosed with AA. The overall purpose of the second study (study 2) is to assess the prevalence and incidence of mental health conditions (depressive episodes, recurrent depressive disorder and anxiety disorder) in adult patients diagnosed with AA relative to a control population of patients without a diagnosis of AA. In addition, the study will determine both the treatment, 'sick day' and unemployment burden. Treatment burden comprises that of medications and psychological interventions used to treat mental health conditions in adult patients diagnosed with Alopecia areata. The overall purpose of the third study (Study 3) is to assess the prevalence and incidence of atopic and autoimmune conditions in adult patients diagnosed with AA relative to a control population of patients without AA. The overall purpose of the fourth study (Study 4) is to assess the incidence of common infections in adult patients diagnosed with AA relative to a control population of patients without AA. ;


Study Design


Related Conditions & MeSH terms

  • Acute Bronchitis
  • Allergic Rhinitis
  • Alopecia
  • Alopecia Areata
  • Ankylosing Spondylitis
  • Anxiety Disorders
  • Arthritis
  • Arthritis, Psoriatic
  • Asthma
  • Atopic Dermatitis
  • Bronchitis
  • Celiac Disease
  • Communicable Diseases
  • Crohn Disease
  • Depressive Disorder
  • Depressive Episode
  • Dermatitis
  • Disease
  • Gastrointestinal Infection
  • Genital Infection
  • Giant Cell Arteritis
  • Graves Disease
  • Hashimoto Disease
  • Hashimoto Thyroiditis
  • Herpes Simplex
  • Herpes Zoster
  • Infection
  • Infection Viral
  • Infections
  • Influenza
  • Lower Resp Tract Infection
  • Lupus Erythematosus, Systemic
  • Multiple Sclerosis
  • Pernicious Anemia
  • Pneumonia
  • Polymyalgia Rheumatica
  • Psoriasis
  • Psoriatic Arthritis
  • Recurrent Depressive Disorder
  • Respiratory Tract Infections
  • Rheumatoid Arthritis
  • Sjogren's Syndrome
  • Skin Infection
  • Spondylitis
  • Spondylitis, Ankylosing
  • Systemic Lupus Erythematosus
  • Thyroiditis
  • Type 1 Diabetes
  • Ulcerative Colitis
  • Upper Respiratory Tract Infection
  • Urinary Tract Infections
  • Virus Diseases
  • Vitiligo

NCT number NCT04239521
Study type Observational
Source Momentum Data
Contact
Status Completed
Phase
Start date October 1, 2020
Completion date November 28, 2022

See also
  Status Clinical Trial Phase
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device